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Over the past few decades, childhood obesity has emerged as a major public health problem in the developed as well as developing countries [1]. It is associated 
with several physical, psychological, metabolic, and hormonal 
disturbances [2,3]. Children with obesity may manifest metabolic 
problems such as dyslipidemia, hypertension, impaired glucose 
tolerance, insulin resistance (IR), hypoferremia, polycystic ovarian 
syndrome, and non-alcoholic steatohepatitis which contribute to the 
risk of cardiovascular diseases and diabetes in later life [2-5]. These 
metabolic problems are attributed to the excess of adipose tissue, 
which works as an endocrine organ [6]. The hormonal problems 
due to obesity result in changes in the plasma concentrations, 
secretory patterns and clearance of various hormones [6]. Of the 
various hormonal disturbances observed in childhood obesity, 
thyroid dysfunction in the form of isolated hyperthyrotropinemia 
is the most common and is often regarded as an adaptive response 
to reduce body weight by increasing the metabolic rate [6]. The 
hyperthyrotropinemia usually reverses after weight loss and does 
not require any specific treatment [6,7]. However, patients are 
often initiated on levothyroxine (LT4) due to a widely prevalent 
belief among clinicians that LT4 treatment along with other obesity 
interventions results in normalization of body weight [6]. In this 
review, we discuss the current evidence on prevalence, mechanisms, 
and the current understanding of replacement therapy with LT4 in 
thyroid dysfunction due to simple obesity in children.
MAGNITUDE OF THE PROBLEM
The average prevalence of thyroid dysfunction in children and 
adolescents with obesity is about 14% (range, 9.2–22.2%) [7-12]. 
A higher prevalence of 17% and 22.2% has been reported from 
Germany and Israel, respectively [7,8], whereas studies from 
Nigeria and Denmark have reported a lower prevalence of about 
10% [9,12]. In the two studies from Turkey, the prevalence of 
isolated hyperthyrotropinemia in childhood obesity was found to 
be 9.2% and 15.3% [10,11]. These studies on thyroid dysfunction 
have included preschool and school going children as well as 
adolescents with age range of 3–18 years (7–12). There is a 
ABSTRACT
Background: Children with simple overweight and obesity may have alterations in the function of various endocrine organs. 
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scarcity of data from developing countries in the prevalence of 
thyroid dysfunction in pediatric obesity [13].
NORMAL METABOLISM OF THYROID HORMONES
The synthesis of thyroid hormones occurs through several enzymatic 
steps in the thyroid gland to secrete thyroxine (T4) as the main 
product. The more active triiodothyronine (T3) is mainly produced 
from deiodination of T4 in peripheral tissues. The homeostatic control 
involves multiple feedback loops and are in turn influenced by various 
genetic, physiological, pathological, and environmental factors; the 
end result of all these is to maintain serum T3 concentrations within the 
normal range. The classic feedback mechanism is the negative control 
exerted by T3 concentrations in plasma as well as in hypothalamus 
and pituitary on the expression and secretion of thyrotropin-releasing 
hormone (TRH) in the hypothalamus and thyroid-stimulating 
hormone (TSH) in the anterior pituitary. TSH regulates the function 
of thyroid gland and promotes the synthesis and activity of Type I 
deiodinases (D1) as a part of its actions. A similar effect is also exerted 
on the activity of Type II deiodinases (D2) in other peripheral tissues 
which have functional TSH receptors, such as brown adipose tissue 
(BAT) and bone [14]. However, the full thermogenic identity of the 
brown adipocyte is provided by the D2-dependent pathways. The 
BAT requires D2-dependent productionS of T3 for its function and 
adipogenesis [14]. Therefore, thyroid hormone-mediated activation 
of the BAT especially in adolescents and adults has a potential role in 
the treatment of obesity [14]. Several other feedback loops include the 
inhibition of its own secretion by TSH and peripheral regulation of 
thyroid hormones that control bioavailability and cellular bioactivity.
PRINCIPAL EFFECTS OF ABNORMAL THYROID 
FUNCTION ON BODY WEIGHT
A close relationship exists between thyroid function and body 
composition. Thyroid hormones are involved in the regulation of 
basal metabolism and thermogenesis and have a significant role in 
lipid and glucose metabolism, food intake, and fat oxidation [15]. 
Thyroid dysfunction, therefore, affects body weight and 
composition, body temperature, and resting energy expenditure 
(REE), and total EE independent of physical activity [15]. In adults, 
untreated subclinical hypothyroidism may lead to significant 
changes in body weight and is considered as a risk factor for 
overweight and obesity [13]. Even minor variations in serum 
TSH due to changes in dosage of levothyroxine during treatment 
of hypothyroidism are associated with significant changes in 
REE [16]. There is, however, a scarcity of data regarding the 
extent of weight gain due to thyroid dysfunction and the extent of 
weight loss attributable to LT4 treatment in hypothyroidism [13].
PROPOSED MECHANISMS OF THYROID DYSFUNCTION 
IN OBESITY
Several mechanisms have been proposed for the alterations in 
thyroid function in obese patients. However, it is not established 
whether these alterations in thyroid function are primary or 
secondary to obesity [6,13]. Changes in thyroid function 
are primarily driven by the dysfunction of adipose tissue as 
weight loss is associated with reversal or mitigation of thyroid 
dysfunction [17]. Conversely, longitudinal studies have shown 
that even minor thyroid dysfunction such as isolated TSH increase 
leads to weight gain and are associated with a significant risk of 
becoming obese [6,18]. The proposed mechanisms for thyroid 
dysfunction in obesity are briefly discussed below. A schematic 
presentation of the main mechanisms is given in Fig. 1.
Adaptive Response to Increase EE
Thyroid hormones play an important role in energy metabolism 
and ATP turnover, especially in inducing thermogenesis by 
stimulating energy uncoupling protein (UCP) [19]. This can 
partly explain the commonly proposed mechanism that the 
increase in TSH and T3 in obese children is an adaptive process 
to increase EE and minimize further weight gain [20]. The 
mechanism is also supported by clinical observations that minor 
changes in serum TSH during treatment of hypothyroidism cause 
significant changes in REE [16]. However, the increase in REE 
may also be due to a concomitant increase in fat-free mass in 
obese individuals [21]. Furthermore, recent data suggests that 
there is no association between EE and concentrations of serum 
TSH, and free T3 and T4 in euthyroid obese individuals [22]. This 
may be due to the impaired thyroid hormone action to induce 
thermogenesis in obese individuals. The adipose tissue especially 
the visceral adipose tissue is shown to have decreased expression 
of thyroid hormone receptors, deiodinases, adrenergic receptors, 
and UCP in patients with obesity [23]. The reduced reactivity 
to hormonal and adrenergic stimuli in adipose tissues leads to a 
lower potential to activate thermogenesis in these patients [23]. 
With weight loss, the concentrations of T3 and TSH also decrease 
and cause a decrease in REE as well as TEE which partly explains 
the difficulties in maintaining the weight loss [7].
Hyperleptinemia Due to Increased Leptin Secretion by 
Adipose Tissue
Leptin is mainly produced by adipocytes and has a major role 
in food intake and energy storage [24,25]. It is involved in the 
regulation of body weight through inhibition of food intake 
and stimulation of EE and locomotor activity. The serum 
concentrations of leptin increase proportionally to the increase 
in body adiposity [24,25]. The consequent hyperleptinemia 
influences the hypothalamic-pituitary-thyroid axis by promoting 
TRH expression and synthesis in paraventricular hypothalamic 
nucleus by a direct action and in arcuate nucleus indirectly leading 
to an increase in TSH secretion by the pituitary gland [25]. Leptin 
also activates proopiomelanocortin neurons and inhibits Agouti-
related protein and neuropeptide Y neurons in the arcuate nucleus. 
As a result, the production of α-melanocyte stimulating hormone 
increases which stimulates the expression of TRH in hypothalamic 
neurons by binding to the melanocortin 4 receptor [26]. Leptin 
also induces the expression of enzymes involved in proteolytic 
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cleavage of pro-TRH to its biologically active form [25]. Leptin 
may also act directly on pituitary to increase TSH secretion as 
leptin receptors are found in the pituitary gland as well. The net 
result of all these actions of leptin on hypothalamic-pituitary 
axis is the increased production of TSH from the pituitary. The 
increased TSH, in turn, may stimulate leptin secretion (TSH helps 
in differentiation of preadipocytes into adipocytes) through its 
receptors on the adipose tissue thus creating a vicious cycle of 
hyperleptinemia and hyperthyrotropinemia [27]. Recent studies 
also indicate the existence of a complex positive feedback 
mechanism between these two hormones [28].
In addition to its actions on the hypothalamic-pituitary axis, 
leptin also influences the metabolism of thyroid hormones by 
altering the activity of deiodinases in various tissues; increase in 
D1 activity in the liver, kidney, and thyroid, and reduction of D2 
activity in BAT and the pituitary gland [25,28]. Hence, while leptin 
seems to increase the local production of T3 in the adipose tissue 
it should be remembered that the reduced expression of thyroid 
hormone receptors in obesity may hamper the local actions of T3.
Resistance to Thyroid Hormones
Obesity may induce a state of resistance similar to genetic form 
of thyroid hormone resistance. The changes in thyroid hormone 
receptors (TR) are primarily observed in the adipose tissue but are 
also present in other tissues [29]. A relative pituitary resistance to 
T3 resulting in increased concentrations of both TSH and T3 is 
also observed in obesity [24]. The decreased tissue responsiveness 
explains the usual findings of increased TSH and T3 in an attempt 
to overcome peripheral resistance [29]. However, recent research 
in this regard has shown conflicting results. The expression of 
TSH receptor and TRα1 in adipose tissue was found to be inversely 
correlated with body mass index (BMI) [29]. The increase in the 
severity of obesity increased the peripheral resistance to thyroid 
hormones leading to an increase in concentrations of TSH and 
T3, and weight loss increased the expression of receptors and a 
consequent fall in hormone concentrations [29]. Similar findings 
of reduced expression of TRs in adipose tissue were observed 
in another study [23]. In contrast to these two studies, a recent 
study showed increased TSH receptor expression in adipocytes of 
overweight individuals and a trend toward increased expression 
of this receptor with increasing BMI [30]. The discrepancies in 
the findings of these studies may be related to the location of 
the adipose tissue studied or an indication of the complexity of 
regulatory actions of thyroid hormones [6].
Increased Concentrations of Inflammatory Cytokines
Obesity is characterized by chronic low grade inflammation 
as evidenced by increase in concentrations of high sensitivity 
C-reactive protein and other inflammatory cytokines [3,31]. 
A positive correlation has indeed been documented between 
markers of inflammation and thyroid function and morphology 
in obese subjects [31]. The underlying mechanism is inhibition of 
mRNA expression of sodium/iodide symporter by inflammatory 
cytokines such as tumor necrosis factor α, interleukin-1, and 
interleukin-6, resulting in reduced iodide uptake in thyroid 
cells [32]. These adipokines may also induce morphological 
abnormalities in thyroid gland [24]. The role of chronic 
inflammation in the regulation of deiodinases in different tissues 
is also speculated but the mechanisms are unclear at present [33].
Influence of Thyroid Autoimmunity
Thyroid autoimmunity may lead to the common finding of 
subclinical hypothyroidism in obesity [34]. The frequent finding 
of a hypoechogenic pattern on thyroid ultrasonography in obese 
patients was thought to be the manifestation of a seronegative 
autoimmune thyroid disease (AITD) that may precede the 
generation of thyroid autoantibodies [34]. Another study 
concluded that obesity is a risk factor for thyroid autoimmunity 
and main cause of acquired thyroid failure in obesity [35]. 
Leptin was suggested as main determinant of autoimmunity, 
leptin concentrations were associated with AITD independent 
of bio-anthropometric variables [35]. This study also noted 
an increased the prevalence of hypothyroidism and thyroid 
autoantibodies in obese subjects as compared to controls [35]. 
A greater prevalence of thyroid autoantibodies in obese children 
as compared to their controls have also been observed in other 
studies [36-38]. However, not all patients with autoantibody 
positivity show evidence of thyroid dysfunction; a majority of 
patients with obesity-related thyroid dysfunction do not have 
autoantibodies [36-39]. Furthermore, observations in morbidly 
obese patients suggest that thyroid autoimmunity may not be 
a major cause of hypothyroidism [40]. The antibody positivity 
rate was found to be much lower in obese patients with untreated 
hypothyroidism as compared to controls (32.1 vs. 66.1%) in this 
study [40]. Thus, the role of thyroid autoimmunity in inducing 
thyroid dysfunction in obesity remains unresolved.
Role of IR
IR is commonly observed in patients with simple overweight and 
obesity [41] similar to patients with secondary obesity [42,43]. 
The hyperinsulinemia stimulates leptin release from adipocytes 
leading to hyperleptinemia which is closely associated with 
features of IR [44,45]. Although a positive association between 
markers of IR and serum TSH has been observed, the underlying 
mechanisms are not clear [44]. The hypothalamic-pituitary-
thyroid axis may be affected by IR in different ways. IR may 
reduce D2 activity in thyrotrophs causing tissue hypothyroidism 
and an increased TSH synthesis [46]. The increased TSH may also 
stimulate the synthesis of inflammatory cytokines by adipocytes 
and promote IR [17]. The increase in T3 concentrations is also 
positively associated with IR [47]. Although T3 is known to 
regulate the metabolic processes of gluconeogenesis, insulin 
secretion and function, the underlying mechanisms of how it 
influences the glucose homeostasis are unclear [6].
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CURRENT CONTROVERSIES RELATED TO LT4 
TREATMENT OF THYROID DYSFUNCTION
In the wake of current understanding that thyroid dysfunction 
may lead to several other metabolic and endocrine alterations 
in obesity, specific therapy with LT4 appears desirable, at least 
theoretically. There is also a widely prevalent belief among 
clinicians that LT4 treatment may be beneficial in normalization 
of body weight [24]. The specific treatment may also help 
overcoming the difficulties in maintaining the weight loss by 
keeping the REE and TEE higher which usually fall as a result 
of fall in the concentrations of T3 and TSH after weight loss 
[7]. However, clinical studies of LT4 supplementation in obesity-
associated thyroid dysfunction have failed to demonstrate 
beneficial effects on body weight [48,49]. In a study in children 
with acquired hypothyroidism, LT4 treatment showed no 
effect on body weight and BMI even after normalization of 
TSH concentrations [50]. A systematic review concluded that 
there is not enough data on the effectiveness of LT4 therapy to 
enhance weight loss and subclinical hyperthyroidism may occur 
as a complication of such therapy [51]. While the data on LT4 
supplementation to treat thyroid dysfunction in obesity remains 
scarce, there are several studies which have shown a normalization 
of this dysfunction with weight loss only [7,24,52-55]. The 
findings and limitations of the major interventional studies are 
summarized in Table 1. The normalization of TSH after weight 
loss without LT4 therapy has also been shown to have beneficial 
effects on insulin sensitivity and leptin levels [55]. The European 
Thyroid Association and several pediatric thyroid societies 
recommend that the decision to initiate LT4 treatment in children 
with TSH <10 mU/L and normal T4 concentrations should be 
taken on an individual basis as there is insufficient evidence for 
the need for such treatment [56,57].
Figure 1: Proposed mechanisms for alterations in thyroid hormone 
levels in obesity. (a) Increased leptin secretion by adipose tissue 
stimulates hypothalamus to increase thyrotropin releasing hormone 
(TRH) which increases thyroid-stimulating hormone (TSH) from 
pituitary. Leptin modulates thyroid gland’s responsiveness to TSH, 
inhibits iodide uptake and expression of sodium/iodide symporter 
and thyroglobulin. Leptin also increases the activity of deiodinases 
(D1). (b) There is a change in the activity of deiodinases (D1, D2, 
and D3) and receptors which promote a state of thyroid hormone 
resistance. (c) The increased adipokines released by the adipose tissue 
affect thyroid gland as well as deiodinases. (d) Insulin resistance 
may reduce deiodinase activity (D2) and increase TSH production 
from the pituitary. (e) The net result is the alterations in thyroid 
hormones concentrations leading to changes in energy expenditure 
and metabolic regulations of body tissues
Table 1: Summary of interventional studies on thyroid dysfunction in childhood obesity
Authors, year, country 
and reference No
Study subjects (mean age) Results and conclusions Limitations
Reinehr T et al., 2002, 
Germany (52)
118 obese and 107 
controls (10.9±2.9 yr)
55 obese children who achieved weight reduction 
showed normalization of T3 and T4 but not TSH, 
without use of thyroxine
Small sample size and 
observation period
Reinehr T et al., 2006, 
Germany (7)
246 obese children (9.5±2.0 yr) 
and 71 controls
Hyperthyrotropinemia improved in 49 obese 
children who showed significant weight loss after 1 
yr intervention based on exercise, behavior therapy, 
and nutrition education
None
Eliakim A et al., 2006, 
Israel (49)
41 obese children (10.6±0.2 yr)
15 received thyroxine
Hyperthyrotropinemia improved in majority of 
children who participated in weight reduction 
intervention, irrespective of thyroxine use
Small sample size
Grandone A et al, 2010, 
Italy (54) 
64 of 398 children
(10.3±2.6 yr) participated in 
weight reduction program
23 out of 64 children showed weight loss and 
concomitant reduction of hyperthyrotropinemia 
indicating no requirement of additional 
levothyroxine
Small sample size
Marras V et al., 2010, 
Italy (53)
43 out of 109 obese children 
with thyroid dysfunction 
underwent lifestyle 
intervention
The thyroid hormone levels of obese children who 
underwent weight reduction program for 6 months 
were compared with normal weight controls. 
Moderate weight loss over 6 months improved 
thyroid dysfunction without use of thyroxine in 
obese children
Selection of non-obese 
controls
Matusik P et al, 2015, 
Poland (48)
51 children
(10.0±3.1 yr), 25 received 
thyroxine 
Normalisation of TSH was similar in children 
treated by dietary-behavioral management as 
compared to those given additional levothyroxine
Retrospective design
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RECOMMENDATIONS FOR FUTURE RESEARCH
There are a number of studies on the effect of weight loss 
on thyroid dysfunction in childhood obesity [7,24,52-54]. 
However, there is limited data on the effect of weight loss on 
different metabolic alterations such as hyperleptinemia, IR, and 
dyslipidemia in obesity which may have a link with the thyroid 
dysfunction [7,55]. In particular, the effect of specific treatment 
of thyroid dysfunction with LT4 on these metabolic changes 
has not been evaluated. There is, thus, a need for acquisition 
of more data to draw conclusions about the beneficial effects 
of LT4 supplementation in childhood obesity. A recent study 
has suggested that thyroid hormones induce browning of white 
adipose tissue and that this mechanism is mediated through 
central effects of these hormones on energy balance [58]. This 
beneficial effect of LT4 treatment in childhood obesity also needs 
exploration in future studies.
CONCLUSIONS
Thyroid dysfunction occurs commonly in children with simple 
overweight and obesity. However, the underlying mechanisms 
of thyroid dysfunction are poorly understood at present. Several 
metabolic alterations such as increased leptin concentrations, 
lipid concentrations, and IR may have a link with thyroid 
dysfunction. The thyroid dysfunction usually reverses after 
weight loss, and hence, specific therapy with LT4 is considered 
inappropriate. However, the data on the effects of specific LT4 
therapy in childhood obesity, other than on weight and body mass 
index, are scarce. Further research should focus on the effects of 
normalization of thyroid function either by weight loss or specific 
LT4 treatment on the various metabolic abnormalities commonly 
occurring with thyroid dysfunction in childhood obesity.
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